Key result
High-dose cardio-selective beta blockers linked to improved survival in HCM.
Why the study?
The study was conducted to evaluate the effectiveness of beta blockers against hypertrophic cardiomyopathy.
Do beta blockers improve survival and outcomes in patients with hypertrophic cardiomyopathy?
Observational (n=136)
No
Do beta blockers improve survival and outcomes in patients with hypertrophic cardiomyopathy?
Cardio-selective beta blockers are effective in managing hypertrophic cardiomyopathy, with outcomes influenced by the left ventricular outflow tract.
May support high-dose cardio-selective beta blockers in elderly HCM with severe LVOT obstruction; leaves open survival effects.
Aim: To evaluate the effectiveness of beta blockers against hypertrophic cardiomyopathy. Study design: Retrospective study Place and duration of study: Department of Medicine, Islam Medical College, Sialkot from 01-10-2020 30-01-09-2021. Methodology: One hundred and thirty six confirmed hypertrophic cardiomyopathy cases within the age of 3-75 years were enrolled. Different types of beta blocker used and its efficacy result and side effects were documented. The average efficacy was assessed for each beta blocker uptil 5 years’ survival rate. Results: High doses of beta blocker were indicated for hypertrophic cardiomyopathy patients in majority of the cases. The efficacy of various beta blockers shows that cardio-selective blocker is much better in efficacy. Left ventricle outflow tract (LVOT) with a value greater or equal to 50 mmHg was observed in patients at or greater than 70 years. Conclusion: Beta blockers are effective in hypertrophy cardiomyopathy cases depending upon the left ventricle out flow tract for better outcome.
No takes yet. Share an insight, caveat, or question.
Bhatti et al. (2022) conducted an observational in Hypertrophic cardiomyopathy (n=136). Beta blockers was evaluated on 5 years' survival rate and efficacy. High doses of beta blockers, particularly cardio-selective agents, were effective for hypertrophic cardiomyopathy, with LVOT ≥50 mmHg observed in patients ≥70 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: